Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
It is very uncertain whether tacrolimus 0.03% changes physician's assessment of global response of improvement, clear or… compared with corticosteroids (very low certainty).
1 finding from 1 review
Recovery long‐term Number of patients at least moderately better · patients with patellofemoral pain syndrome (symptoms > 1 month (3 studies); symptoms > 2 months (1 study); symptoms > 3 months (2…
It is very uncertain whether target of exercise: hip + knee changes recovery long‐term Number of patients at least moderately better compared with knee exercises (very low certainty).
1 finding from 1 review
Intervention not reported
At least 30% reduction in pain or equivalent (moderate) · adults with fibromyalgia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Episodes of moderate/severe sore throat(subgroup of severely affected patients) Including as 1 episode the period post‐surgery) · Children with chronic/recurrent acute tonsillitis
1 finding from 1 review
Episodes of moderate/severe sore throat(subgroup of moderately affected patients) Not including as 1 episode the period post‐surgery · Children with chronic/recurrent acute tonsillitis
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · people with asthma
Subcutaneous omalizumab + steroid probably leads to lower number of participants with at least one exacerbation Moderate to… compared with placebo + steroid (stable steroid) (moderate certainty).
1 finding from 1 review
Intervention not reported
"Moderate" benefit At least 30% reduction in pain · adults with neuropathic pain (Trigeminal neuralgia, painful diabetic neuropathy, chronic post stroke pain)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
"Moderate" benefit At least 30% reduction in pain · Adults with cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
OHSS · subfertile women
GnRH agonist probably leads to lower OHSS (mild, moderate or severe): overall risk compared with HCG (moderate certainty).
1 finding from 1 review
Moderate or severe OHSS · subfertile women
GnRH agonist probably leads to lower OHSS (moderate or severe): overall risk compared with HCG (moderate certainty).
1 finding from 1 review
OHSS (mild, moderate or severe) in women at high risk of OHSS · subfertile women
GnRH agonist probably leads to lower OHSS (mild, moderate or severe) in women at high risk of OHSS compared with HCG (moderate certainty).
1 finding from 1 review
Physical health behaviour moderate or vigorous physical activity · people with severe mental disorders
1 finding from 1 review
Number of patients with moderate/severe pain (1 hour postoperatively) · children undergoing surgery
Nalbuphine may leads to lower number of patients with moderate/severe pain (1 hour postoperatively) compared with placebo (low certainty).
2 findings from 1 review
Number of patients with moderate/severe pain (1 hour postoperatively) · children undergoing surgery
1 finding from 1 review
Number of patients with moderate/severe pain (1 hour postoperatively) · children undergoing surgery
1 finding from 1 review
Number of patients with moderate/severe pain (1 hour postoperatively) · children undergoing surgery
Nalbuphine showed no clear difference in number of patients with moderate/severe pain (1 hour postoperatively) compared with morphine (low certainty).
2 findings from 1 review
Number requiring additional analgesia required postoperatively ‐ moderate quality studies · patients with postoperative pain
High dose clonidine may leads to lower number requiring additional analgesia required postoperatively ‐… compared with low dose clonidine (low certainty).
1 finding from 1 review
Inflammation: participants with no swelling at 72 hours (canakinumab 150 mg) Assessed by the investigator as no swelling, mild/palpable, moderate/visible, severe/bulging beyond the joint margins · acute gout
Canakinumab probably leads to higher inflammation: participants with no swelling at 72 hours (canakinumab… compared with triamcinolone acetonide (moderate certainty).
1 finding from 1 review
Intervention not reported
"Moderate" benefit At least 30% reduction in pain · neuropathic pain (5 studies in painful diabetic neuropathy and polyneuropathy)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Patient Global Impression of Change much or very much improved (patient global evaluation of pain relief complete, good or moderate) · neuropathic pain (6 studies in central neuropathic pain due to multiple sclerosis, spinal cord injury, polyneuropathy, central post‐stroke…
1 finding from 1 review